- Telehealth Visits
- Insurance plan information
Ernest Y. Lee, MD, PhD
He | Him | HisDermatology- Telehealth Visits
- Insurance plan information
Ernest Y. Lee, MD, PhD
He | Him | HisDermatology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Ernest Y. Lee is a dermatologist and physician-scientist who cares for patients with a broad range of skin conditions and concerns.
In his research, Lee uses bioinformatics and machine learning (systems and tools that can organize large amounts of health information) to study how dysregulation in the immune system leads to inflammation in the skin. His overarching goal is to discover and design novel treatments for inflammatory skin diseases.
Lee earned his medical degree as well as a doctorate in bioengineering from the University of California, Los Angeles. He completed a residency in dermatology at UCSF. He is currently a postdoctoral fellow in computational immunology at the UCSF Bakar Computational Health Sciences Institute.
In addition to providing patient care and pursuing research, Lee takes pride in educating future dermatologists.
Education & training
Board certification
- Dermatology, American Board of Dermatology/Dermatopathology
- American Board of Dermatology/Dermatopathology
Residency
- Dermatology, University of CA at San Francisco- Dermatology GME
Internship
- Internal Medicine, Cedars-Sinai Medical Center GME
Degree
- MD, UCLA David Geffen School of Medicine
My expertise
Specialties
Locations
Clinical Trials query: q=health_gateway_id_ss%3A%28%224086%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%224086%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.